

# بسم الله الرحمن الرحيم





# شبكة المعلومات الجامعية

## التوثيق الالكتروني والميكروفيلم



# جامعة عين شمس

التوثيق الإلكتروني والميكرو فيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





# بعض الوثائق الأصلية تالفة







# بالرسالة صفحات لم ترد بالأصل



# **THE ROLE OF PROPHYLACTIC METHYLENE BLUE IN MANAGEMENT OF POST CARDIOPULMONARY BYPASS VASOPLÉGIA IN HIGH RISK PATIENTS**

## **Thesis**

Submitted for partial fulfillment  
Of the M.D. Degree in Anesthesiology

## **By**

**AHMED SALAH EL DIN OMRAN**

M.B.B. Ch, M.Sc. Anesthesiology

## **Under supervision of**

**Prof. Dr. Samia Ibrahim Sharaf**

Professor of Anesthesiology and Intensive care  
Faculty of Medicine Ain Shams University

**Dr. Hala Ezzat Ali Eid**

Assissant Professor of Anesthesiology and Intensive care  
Faculty of Medicine Ain Shams University

**Dr. Adel Mohamed Alansary**

Assissant Professor of Anesthesiology and Intensive care  
Faculty of Medicine Ain Shams University

Faculty of Medicine  
Ain Shams University

2010

---

# CONTENTS

INTRODUCTION & AIM OF THE WORK .....	
REVIEW OF LITERATURE .....	
THE SYSTEMIC INFLAMMATORY RESPONSE...	
DURING CBP .....	
Vasoplegic syndrome and new .....	
Methods of treatment.....	
PATIENTS AND METHODS.....	
RESULTS .....	
DISCUSSION.....	
SUMMARY AND CONCLUSION.....	
REFERENCES .....	
ARABIC SUMMARY .....	

---

# LIST OF TABLES

<b>Table No.</b>	<b>Title</b>	<b>Page No.</b>
1	Demographic analysis and preoperative medical conditions.....	
2	Mean arterial pressure variables.....	
3	Mean Pulmonary artery pressure.....	
4	Pulmonary vascular resistance .....	
5	Systemic vascular resistance .....	
6	Central venous pressure.....	
7	Cardiac output variables .....	
8	The laboratory variables .....	
9	comparison between the study group and the control group regarding the volume of fluid infused, fresh frozen plasma, packed RBCs, urine output, aortic crossclamp period or total CPB time.....	
10	The need for inotropes, hospital stay, and ICU length of stay.....	



---

# LIST OF FIGURES

<b>Fig. No.</b>	<b>Title</b>	<b>Page No.</b>
1	Mechanism of arrest and transmigration of neutrophils into the interstitial space.....	
2	Steps in activation of the classical and alternative complement pathways and formation of the membrane attack complex, C5b-9. ....	
3	Schematic of the inflammatory process induced by CPB. ....	
4	Pathways leading to activation of NF-KB and the production of adhesion molecules. ....	

---

## LIST OF GRAPHS

Fig. No.	Title	Page No.
1	Showing increase in the MAP more in the study group than the control group. ....	
2	Showing an increase in the pulmonary vascular resistance value at the study group more than the control. ....	
3	Showing an increase in the systemic vascular resistance value at the study group more than the control. ....	
4	Showing an increase in the central venous pressure value at the study group more than the control. ....	
5	Showing an increase in the cardiac output value at the study group more than the control. ....	
6	Showing the heart rates of both groups with no significant difference between the two groups ....	
7	Showing the marked difference between the study group and the control group in their need for adrenaline being higher in the control group. ....	
8	Showing the difference between the two groups regarding their need for noradrenaline...	

---

# ABBREVIATIONS

<b>(ACLS)</b>	Adult cardiopulmonary life support
<b>(ADH)</b>	Antidiuretic hormone
<b>(AVP)</b>	Arginine vasopressin
<b>(cno)</b>	Constitutive nitric oxide
<b>(CPB)</b>	Cardiopulmonary bypass
<b>(EC)</b>	Endothelial cell
<b>(ECP)</b>	Extracorporeal circulation
<b>(ENA)</b>	Endothelial cell neutrophil attractant
<b>(GMP)</b>	Cyclic guanosine monophosphate
<b>(ICAM)</b>	intracellular adhesion molecule
<b>(IFN)</b>	Interferon
<b>(INOS)</b>	Inducible nitric oxide synthetases
<b>(LVAD)</b>	Left sided assisted device
<b>(NAP)</b>	Neutrophil activating protein
<b>(NF-KB)</b>	Nuclear factor KB
<b>(NO)</b>	Nitric oxide
<b>(OHS)</b>	open heart surgery
<b>(PAF)</b>	Platelet activating factor
<b>(PSGL-1)</b>	P-selectin glycoprotein-1
<b>(TNF)</b>	Tumour necrosis factor
<b>(VCAM)</b>	vascular adhesion molecule
<b>(vs)</b>	vasoplegic syndrome

# INTRODUCTION

The English surgeon John Hunter first recognized the malignant systemic spread of inflammation as an abnormal response to injury two centuries ago . The early pioneers in cardiac surgery recognized a similar pattern of systemic injury they encountered after cardiopulmonarybypass (CPS). Kirklin hypothesized that the deleterious effects of CPB were secondary to the exposure of blood to abnormal surfaces in the bypass circuit, which initiated a "whole body inflammatory response." He noted that this response is characterized by activation of coagulation, the kallikrein system, fibrinolysis,, and complement, all of which are now recognized as the mediators of the disseminated intravascular post-pump syndrome(*kirklin et al, 1991*)

Many of the components currently used to perform cardiovascular operations lead to systemic insults that result from cardiopulmonary bypass circuit-induced contact activation, circulatory shock, and resuscitation, and a syndrome similar to endotoxemia. Experimental observations have demonstrated that these events have profound effects on activating endothelial cells to recruit neutrophils from the circulation. Once adherent to the endothelium, neutrophils release cytotoxic proteases and oxygen-derived free radicals, which are responsible for much of the end-organ damage seen after cardiovascular operations. Recently the cellular and molecular mechanisms of endothelial cell activation have

become increasingly understood. It is conceivable that once the molecular mechanisms of endothelial cell activation are better defined, therapies will be developed allowing the selective or collective inhibition of vascular endothelial activation during; the perioperative period. (*Edward et al,1997*)

Within the body the endothelial cell, the only surface in contact with circulating blood, simultaneously maintains the fluidity of blood and the integrity of the vascular system. This remarkable cell maintains a dynamic equilibrium by producing anticoagulants to maintain blood in a fluid state and by generating procoagulant substances to enhance gel formation when perturbed. Coagulation proteins circulate as inert zymogens, which convert to active enzymes when stimulated. Likewise, blood cells remain quiescent until activated to express surface receptors and release proteins and enzymes involved in the coagulation equilibrium. The continuous exposure of heparinized blood to the perfusion circuit and to nonendothelial cell tissues of the wound during clinical cardiac surgery produces an intense thrombotic stimulus that involves both the tissue factor pathway (extrinsic coagulation pathway) in the wound and the contact and intrinsic coagulation pathways in the perfusion circuit. Heparin does not block thrombin formation; during extracorporeal perfusion (ECP) heparin partially inhibits thrombin after it is produced. Thrombin is continuously generated and circulated despite massive doses of heparin in all applications of extracorporeal perfusion, (*Spanier et al 1996*)

## **AIM OF THE WORK**

The aim of the study is to detect the effect of prophylactic administration of methylene blue in high group for vasoplegic syndrome and its effect on morbidity, mortality, Intensive care and vasopressor requirement.

# SYSTEMIC INFLAMMATORY RESPONSE

## (1) Endothelial cells

Endothelial cells are activated during CPB and, open heart surgery (OHS) by a variety of agonists. The principal agonists for endothelial cell activation during CPB are thrombin, C5a, and the cytokines IL-1B and TNF. Other agonists, such as endotoxin, histamine are less important during CPB, and endothelial cells are largely unresponsive to chemokines. (*Francis et al2001*).

IL-1B and TNF induce the early expression of P-selectin and the later synthesis and expression of E-selectin, which are involved in the initial stages of neutrophil and monocyte adhesion. The two cytokines also induce expression of intracellular adhesion molecule(ICAM-1) and vascular adhesion molecule( VCAM1), which firmly bind neutrophils and monocytes to the endothelium and initiate leukocyte trafficking to the extravascular space ( Fig. 1). Experimentally ICAM-1 is upregulated during CPB in pulmonary vessels and there is evidence that P- and E-selectins are upregulated during CPB and in myocardial ischemia-reperfusion sequences. IL-1B and TNF-, induce endothelial cell production of the chemotactic proteins IL-8 and MCP-1, and induce production of prostacyclin by the cyclooxygenase pathway and nitric oxide( NO) by NO synthase. These two vasodilators reduce shear stress and increase vascular permeability and therefore enhance leukocyte adhesion and transmigration. Lastly, IL-1 $\beta$  and TNF, stimulate endothelial cell production of proinflammatory cytokines, IL-1, IL-6, IL-8, and platelet